GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Cyclically Adjusted Price-to-FCF

Regenetp (Regenetp) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Regenetp Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenetp Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Regenetp's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Cyclically Adjusted Price-to-FCF Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenetp's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Regenetp's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regenetp's Cyclically Adjusted Price-to-FCF falls into.



Regenetp Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Regenetp's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenetp's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.694/127.3478*127.3478
=-0.694

Current CPI (Mar. 2023) = 127.3478.

Regenetp Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201304 -31.667 98.107 -41.105
201307 -171.641 98.557 -221.782
201310 -132.535 98.536 -171.289
201401 17.070 98.692 22.026
201404 -32.581 100.023 -41.482
201407 5.390 100.520 6.829
201410 -79.302 100.176 -100.812
201501 53.070 98.604 68.541
201504 -31.818 99.824 -40.591
201507 -33.423 100.691 -42.271
201510 -10.243 100.346 -12.999
201601 -5.940 99.957 -7.568
201604 -8.147 100.947 -10.278
201607 -5.181 101.524 -6.499
201610 -2.130 101.988 -2.660
201701 -14.172 102.456 -17.615
201704 -14.431 103.167 -17.813
201707 -10.291 103.278 -12.689
201710 -13.197 104.070 -16.149
201801 -29.196 104.578 -35.553
201804 -13.042 105.708 -15.712
201807 -11.029 106.324 -13.210
201810 -16.868 106.695 -20.133
201903 -20.955 107.251 -24.882
201906 -12.910 108.070 -15.213
201909 -11.493 108.329 -13.511
201912 -15.143 108.420 -17.787
202003 -11.244 108.902 -13.149
202006 -7.632 108.767 -8.936
202009 -4.395 109.815 -5.097
202012 -3.015 109.897 -3.494
202103 -2.167 111.754 -2.469
202106 -1.263 114.631 -1.403
202109 -1.413 115.734 -1.555
202112 -2.261 117.630 -2.448
202203 -1.698 121.301 -1.783
202206 -1.518 125.017 -1.546
202209 -0.560 125.227 -0.569
202212 -0.528 125.222 -0.537
202303 -0.694 127.348 -0.694

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenetp  (OTCPK:RGTPQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Regenetp Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Regenetp's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (Regenetp) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
Executives
Peter A Cohen director 40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg director 1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague officer: Chief Operating Officer 1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler other: General Counsel 1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer director 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen director POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann officer: Chief Financial Officer C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson officer: Chief Financial Officer 14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough 10 percent owner, other: Prior D&O within 90 days 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann director 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson director, officer: Chief Operating Officer 181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan director 1943, ROSECREST DRIVE, OAKLAND CA 94602